Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Gilead-Bristol Hepatitis C Combo Cures 100% of Patients in Study

A combination of hepatitis C drugs from Gilead Sciences Inc. (GILD) and Bristol-Myers Squibb Co. (BMY) cured 100 percent of patients in a trial, showing the success of a cocktail that doctors say they want yet may never be approved.

Published
28 April 2013
From
Businessweek
AbbVie interferon-free combination cures over 90% of hepatitis C genotype 1

A four-drug combination of direct acting antivirals developed by AbbVie cured hepatitis C infection in over 90% of participants in the AVIATOR study, without the need for

Published
26 April 2013
By
Keith Alcorn
Sofosbuvir + ribavirin cures most genotype 2 hepatitis C, but genotype 3 response is lower

A dual oral regimen containing the hepatitis C nucleotide polymerase inhibitor sofosbuvir plus ribavirin produced high sustained virological response rates overall, but this was driven by very

Published
26 April 2013
By
Liz Highleyman
Sofosbuvir Offers High Cure Rate For Two Hepatitis C Subtypes -

Sofosbuvir, a new drug, is offering impressive cure rates for Hepatitis C patients with two subtypes of the disease - genotypes 2 and 3, according to researchers led by Weill Cornell Medical College.

Published
24 April 2013
From
Medical News Today
Investigational compound faldaprevir shows high viral cure and early treatment success in treatment-naïve patients with genotype-1 hepatitis C

In the Phase III clinical trial STARTVerso™1, up to 80% of patients treated with faldaprevir+ and PegIFN/RBV achieved viral cure (SVR12).

Published
24 April 2013
From
Boehringer-Ingelheim press release
Medivir: New Data from Simeprevir Phase III Studies Quest 1 and 2 in Hepatitis C Patients will be Presented at EASL 23-28 April in Amsterdam Read more: Medivir: New Data from Simeprevir Phase III Studies Quest 1 and 2 in Hepatitis C Patients will be Pres

These primary efficacy and safety results from two global phase III studies demonstrate that use of the investigational protease inhibitor simeprevir led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively, of treatment-naïve genotype 1 chronic hepatitis C adult patients with compensated liver disease, when administered once daily with pegylated interferon and ribavirin.

Published
24 April 2013
From
Medivir press release
AbbVie hepatitis C drugs knock out virus at eight weeks

A combination of five oral drugs being tested by AbbVie Inc cured at least 88 percent of new patients with hepatitis C after only eight weeks of treatment, without raising significant safety issues, researchers said on Tuesday.

Published
24 April 2013
From
Yahoo News
Bristol-Myers oral hepatitis C regimen looks competitive -study

The combination therapy, which involves three direct acting antiviral drugs that each attack different targets needed for replication of the hepatitis virus, achieved cure rates as high as 94 percent when given for either 12 weeks or 24 weeks, according to results of the small study.

Published
24 April 2013
From
Reuters
The Hepatitis C Drug Pipeline Report: A Groundswell to Become a Sea Change

Frantic competition between the major pharmaceutical players has accelerated progress on new hepatitis C virus (HCV) therapies to a breakneck speed.

Published
19 April 2013
From
Hep: Your Guide to Hepatitis
Roche to commercialize Hepatitis C drug in China with Ascletis

Swiss drugmaker Roche Holding AG said it had teamed up with biotech firm Ascletis to develop and commercialize its investigative drug danoprevir in China for the treatment of the Hepatitis-C virus.

Published
15 April 2013
From
Yahoo! News

Filter by country